EDAP TMS SA : EDAP TMS SA to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Monday, April 1, 2019
Company to host conference call and webcast on Tuesday, April 2 at 8:30am EDT
LYON, France, March 21, 2019 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2018 after the financial markets close on Monday, April 1, 2019.
An accompanying conference call and webcast will be conducted by Philippe Chauveau, Chairman of the Board, Marc Oczachowski, Chief Executive Officer; and François Dietsch, Chief Financial Officer, to review the results. The call will be held at 8:30am EDT on Tuesday, April 2, 2019. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Call & Webcast
Tuesday, April 2nd @ 8:30am Eastern Time
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm® Robotic HIFU and Ablatherm® Fusion. As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith® range of ESWL systems. For more information on the Company, please visit https://www.edap-tms.com, and us.hifu-prostate.com.
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
LifeSci Advisors, LLC
Upcoming Life Sciences Events
- May 2019
- Zurich: The Pharma Licensing Negotiation Course
- Zurich: Pharma-Biotech Product & Company Valuation
- Zurich: The Pharmaceutical Out-licensing Course